Tnf Pharmaceuticals shares surge 28.99% intraday after agreement with Prevail Partners for stock purchase and clinical research support.

Tnf Pharmaceuticals, Inc. surged 28.99% intraday after announcing an agreement with Prevail Partners, including the purchase of 283,019 shares of TNFA common stock at $2.12 per share and the provision of clinical research services to support MYMD-1 clinical development. The company focuses on developing the oral TNF-α inhibitor Isomyosamine for the treatment of immune-inflammatory diseases, differentiating itself from injectable forms and possessing blood-brain barrier penetration capabilities.